相似文献
1
First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.CAR NK-92细胞的首次人体临床试验：CD33-CAR NK-92细胞在复发难治性急性髓系白血病患者中的安全性测试。
Am J Cancer Res. 2018 Jun 1;8(6):1083-1089. eCollection 2018.
2
Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.勘误：CAR NK-92细胞的首次人体临床试验：CD33-CAR NK-92细胞在复发难治性急性髓系白血病患者中的安全性测试。
Am J Cancer Res. 2018 Sep 1;8(9):1899. eCollection 2018.
3
CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.不同共刺激分子的 CD33 特异性嵌合抗原受体 T 细胞表现出强大的抗白血病疗效和不同的表型。
Hum Gene Ther. 2018 May;29(5):626-639. doi: 10.1089/hum.2017.241. Epub 2018 Mar 19.
4
Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia.工程化靶向CD33的嵌合抗原受体自然杀伤细胞（CAR-NK细胞）并同时胞外分泌抗CD16抗体，对髓系白血病显示出卓越的抗肿瘤效果。
Cancer Lett. 2023 Apr 1;558:216103. doi: 10.1016/j.canlet.2023.216103. Epub 2023 Feb 17.
5
Cellular therapy for acute myeloid Leukemia - Current status and future prospects.急性髓细胞白血病的细胞治疗：现状与未来展望。
Blood Rev. 2019 Sep;37:100578. doi: 10.1016/j.blre.2019.05.002. Epub 2019 May 11.
6
A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.一种用于治疗急性髓系白血病的独特的仅含人免疫球蛋白重链可变区的CD33嵌合抗原受体
Front Oncol. 2018 Nov 22;8:539. doi: 10.3389/fonc.2018.00539. eCollection 2018.
7
Biomarkers as targets for CAR-T/NK cell therapy in AML.生物标志物作为急性髓系白血病中CAR-T/NK细胞疗法的靶点。
Biomark Res. 2023 Jun 17;11(1):65. doi: 10.1186/s40364-023-00501-9.
8
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.FDA 批准概要：Mylotarg 用于治疗复发或难治性 CD33 阳性急性髓系白血病患者。
Oncologist. 2018 Sep;23(9):1103-1108. doi: 10.1634/theoncologist.2017-0604. Epub 2018 Apr 12.
9
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病：改变复发难治性疾病的治疗方式
Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x.
10
CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia-Recent Advances.嵌合抗原受体T细胞免疫疗法治疗急性髓系白血病的最新进展
Cancers (Basel). 2023 May 27;15(11):2944. doi: 10.3390/cancers15112944.
引用本文的文献
1
Adoptive Cellular Therapies in Pediatric Leukemia Patients After Allogeneic-Hematopoietic Stem Cell Transplants.异基因造血干细胞移植后儿童白血病患者的过继性细胞疗法
Immune Netw. 2025 Aug 12;25(4):e29. doi: 10.4110/in.2025.25.e29. eCollection 2025 Aug.
2
Recent advances in tumor immunotherapy based on NK cells.基于自然杀伤细胞的肿瘤免疫疗法的最新进展。
Front Immunol. 2025 Aug 7;16:1595533. doi: 10.3389/fimmu.2025.1595533. eCollection 2025.
3
Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions.基于嵌合抗原受体的免疫疗法靶向癌症干细胞：生物学、证据及未来方向
Cancer Cell Int. 2025 Jul 28;25(1):289. doi: 10.1186/s12935-025-03846-3.
4
Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses.分泌双特异性杀伤细胞衔接器的嵌合抗原受体T细胞重定向自然杀伤细胞特异性以增强抗肿瘤反应。
Nat Biomed Eng. 2025 Jul 14. doi: 10.1038/s41551-025-01450-4.
5
Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities.癌症干细胞与免疫疗法的关联：关键见解、挑战及潜在治疗机遇
Cancers (Basel). 2025 Jun 23;17(13):2100. doi: 10.3390/cancers17132100.
6
Does a natural killer need a CAR?自然杀伤细胞需要嵌合抗原受体吗？
Front Immunol. 2025 Jun 26;16:1606126. doi: 10.3389/fimmu.2025.1606126. eCollection 2025.
7
CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?嵌合抗原受体T细胞疗法治疗急性髓系白血病：我们目前的进展如何？
Curr Oncol. 2025 May 30;32(6):322. doi: 10.3390/curroncol32060322.
8
CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy.嵌合抗原受体自然杀伤细胞（CAR-NK细胞）：利用自然杀伤细胞的力量进行晚期癌症治疗。
Front Immunol. 2025 May 30;16:1603757. doi: 10.3389/fimmu.2025.1603757. eCollection 2025.
9
Application and prospects of genetic engineering in CAR-NK cell therapy.基因工程在CAR-NK细胞疗法中的应用与前景
Front Immunol. 2025 May 23;16:1600411. doi: 10.3389/fimmu.2025.1600411. eCollection 2025.
10
Prospects and applications of NK therapy in the treatment of gliomas (Review).NK细胞疗法在胶质瘤治疗中的前景与应用（综述）
Oncol Rep. 2025 Aug;54(2). doi: 10.3892/or.2025.8921. Epub 2025 Jun 6.
本文引用的文献
1
NK cell-based immunotherapy for cancer.基于自然杀伤细胞的癌症免疫疗法。
Semin Immunol. 2017 Jun;31:37-54. doi: 10.1016/j.smim.2017.07.009. Epub 2017 Aug 31.
2
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.经基因工程改造表达 IL-15 和靶向 CD19 的 CAR 的脐血 NK 细胞具有长期持久性和强大的抗肿瘤活性。
Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20.
3
Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.嵌合抗原受体T细胞靶向FLT3用于治疗急性髓系白血病。
Leukemia. 2017 Aug;31(8):1830-1834. doi: 10.1038/leu.2017.147. Epub 2017 May 12.
4
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.人急性髓系白血病中CD33转录变体的表达及功能特性
Oncotarget. 2016 Jul 12;7(28):43281-43294. doi: 10.18632/oncotarget.9674.
5
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.表皮生长因子受体嵌合抗原受体自然杀伤细胞与溶瘤性单纯疱疹病毒1联合治疗乳腺癌脑转移
Oncotarget. 2016 May 10;7(19):27764-77. doi: 10.18632/oncotarget.8526.
6
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.CD19嵌合抗原受体工程化的NK-92细胞足以克服B细胞恶性肿瘤中的NK细胞抗性。
J Cell Mol Med. 2016 Jul;20(7):1287-94. doi: 10.1111/jcmm.12810. Epub 2016 Mar 23.
7
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.针对胶质母细胞瘤的靶向治疗的 ErbB2/HER2 特异性 NK 细胞。
J Natl Cancer Inst. 2015 Dec 6;108(5). doi: 10.1093/jnci/djv375. Print 2016 May.
8
9
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.表达ErbB2/HER2特异性嵌合抗原受体的克隆性自然杀伤细胞对肿瘤生长的选择性抑制作用
Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6.
10
Are natural killer cells superior CAR drivers?自然杀伤细胞是更出色的嵌合抗原受体（CAR）驱动细胞吗？
Oncoimmunology. 2014 Apr 15;3:e28147. doi: 10.4161/onci.28147. eCollection 2014.
Zotero 插件